[18], estimated liraglutide eligibility and potential preventable events among the US National Health and Nutrition examination estimated population of 27.3 million persons with diabetes, 15.4% (4.2 million) fit LEADER eligibility criteria, and based on LEADER cardiovascular outcome risk reductions from the 1.8 mg liraglutide (or maximally tolerated dose) used in the trial, we estimated 21,209 primary composite CVD events, 29,691 extended CVD composite outcomes, 16,967 all-cause deaths, 16,967 cardiovascular deaths, and 12,725 myocardial infarctions could potentially be prevented annually
It also helps with the repair of tendons, ligaments, and bones, supporting overall tissue regeneration
R., ODorisio, T
This might be tougher to reach on your own, but it's a good rotation alternative